

Company Heartbeats

Swiss companies - Position yourself with UBS Warrants for upcoming financial results

Company Heartbeats regularly lists companies that will soon present their financial results and for which UBS is offering suitable Warrants. The Warrants are listed on the SIX Structured Products Exchange and tradable on every trading day under normal market conditions. Please consider the disclaimer at the end of this document.

Date	Company	Publication	Share price	Suitable Warrants						
				Type	SIX symbol	Expiry	Leverage	Strike	Ask price	More Warrants
17 Feb 26	Basilea Pharm.	Annual report	CHF 56.30	Call	SADBJU	19 Jun 26	7.28	60.00	0.13	Calls on Basilea Pharm.
17 Feb 26	DKSH	Annual report	CHF 60.40	Call	B8ZS9U	19 Jun 26	14.50	65.00	0.05	Calls on DKSH
18 Feb 26	Sunrise	Annual report	CHF 46.50	Call	SO3BDU	19 Jun 26	7.56	48.00	0.12	Calls on Sunrise
18 Feb 26	Straumann	Annual report	CHF 96.92	Call	B5SSQU	19 Jun 26	6.76	100.00	0.33	Calls on Straumann
19 Feb 26	Zurich Insurance	Annual report	CHF 559.20	Call	SZUR7U	19 Jun 26	17.28	580.00	0.22	Calls on Zurich Insurance
				Put	SA2BDU	19 Jun 26	10.53	540.00	0.51	Puts on Zurich Insurance
19 Feb 26	Nestle	Annual report	CHF 79.86	Call	BNRSQU	19 Jun 26	13.11	84.00	0.12	Calls on Nestle
				Put	SHOB7U	19 Jun 26	10.94	75.00	0.18	Puts on Nestle
20 Feb 26	Siegfried	Annual report	CHF 89.90	Call	B6PSQU	19 Jun 26	7.79	95.00	0.15	Calls on Siegfried
20 Feb 26	Sika	Annual report	CHF 155.10	Call	SYMBGU	19 Jun 26	8.34	160.00	0.16	Calls on Sika
				Put	S3UBIU	19 Jun 26	7.24	150.00	0.18	Puts on Sika
24 Feb 26	Temenos Group	Annual report	CHF 63.90	Call	S1PBEU	19 Jun 26	4.92	66.00	0.26	Calls on Temenos Group
24 Feb 26	Alcon	Annual report	CHF 60.58	Call	BICSNU	19 Jun 26	8.65	64.00	0.14	Calls on Alcon
				Put	SY3B8U	19 Jun 26	6.63	60.00	0.21	Puts on Alcon
24 Feb 26	Dormakaba	Semi-annual report	CHF 62.00	Call	SMTBUU	19 Jun 26	8.82	65.00	0.13	Calls on Dormakaba
25 Feb 26	Sandoz	Annual report	CHF 66.22	Call	S8WBKU	19 Jun 26	7.86	70.00	0.32	Calls on Sandoz

Source: Refinitiv, UBS.

As of: 16 Feb 26. All prices are indicative.

Company Heartbeats

International companies - Position yourself with UBS Warrants for upcoming financial results

Company Heartbeats regularly lists companies that will soon present their financial results and for which UBS is offering suitable Warrants. The Warrants are listed on the SIX Structured Products Exchange and tradable on every trading day under normal market conditions. Please consider the disclaimer at the end of this document.

Date	Company	Publication	Share price	Suitable Warrants						
				Type	SIX symbol	Expiry	Leverage	Strike	Ask price	More Warrants
18 Feb 26	Alibaba	Q3 result	USD 155.73	Call	S07B8U	18 Jun 26	7.14	170.00	0.48	Calls on Alibaba
25 Feb 26	Bayer	Annual report	EUR 45.86	Call	SPKBJU	19 Jun 26	6.67	48.00	0.33	Calls on Bayer
25 Feb 26	NVIDIA	Annual report	USD 182.81	Call	SUGBUU	18 Jun 26	6.34	190.00	0.30	Calls on NVIDIA
06 Mar 26	Lufthansa	Annual report	EUR 9.12	Call	SBOBFU	19 Jun 26	7.96	9.50	0.11	Calls on Lufthansa
10 Mar 26	Volkswagen	Annual report	EUR 103.15	Call	SLYBBU	19 Jun 26	8.94	110.00	0.09	Calls on Volkswagen
11 Mar 26	Rheinmetall	Annual report	EUR 1,626.00	Call	SAFB4U	19 Jun 26	5.96	1,700.00	1.31	Calls on Rheinmetall
18 Mar 26	Micron Technology	Semi-annual report	USD 411.66	Call	SU8B1U	18 Jun 26	4.28	440.00	0.51	Calls on Micron Technology
15 Apr 26	Netflix	Q1 result	USD 76.87	Call	S2TB9U	18 Sep 26	6.20	85.00	0.57	Calls on Netflix
20 Apr 26	Tesla	Q1 result	USD 417.44	Call Put	S3JBVU SGQBHU	18 Sep 26 18 Sep 26	4.67 3.88	430.00 410.00	0.51 0.42	Calls on Tesla Puts on Tesla
22 Apr 26	Alphabet	Q1 result	USD 306.02	Call	S9CB4U	18 Sep 26	6.63	320.00	0.24	Calls on Alphabet
23 Apr 26	SAP	Q1 result	EUR 171.44	Call	SJOBPU	18 Sep 26	6.86	180.00	0.25	Calls on SAP
27 Apr 26	Paypal	Q1 result	USD 40.29	Call	S2LB5U	18 Sep 26	5.44	42.00	0.08	Calls on Paypal

Source: Refinitiv, UBS.

As of: 16 Feb 26. All prices are indicative.

Disclaimer

This material has been prepared by UBS AG or one of its affiliates ("UBS"). This material is only intended for the distribution permitted under the applicable law. It has not been prepared for the needs of a specific recipient. It is only published for information purposes and does not constitute an offer or an invitation to purchase or sell securities or associated financial instruments ("Instruments"). UBS accepts no liability (either expressly or tacitly) for the completeness or reliability of the information contained in this document, except for the information on UBS AG and its affiliates. The information should not be regarded by the recipients as a substitute for their own judgment. All the opinions contained herein may change without prior notice and contradict the opinions of other business areas of UBS due to the application of different assumptions and criteria. UBS is not obliged to keep the information up to date. UBS, its executives, employees or clients may have or have had a participation in the Instruments and may conclude transactions with them at any time. UBS may maintain or have maintained a relationship with the entities specified in this information. Neither UBS nor its affiliates, executives or employees are liable for losses resulting from the use of this information.

Structured derivatives do not constitute participation in collective investment schemes. For this reason they do not require approval from the Swiss Financial Market Supervisory Authority (FINMA). As a result, investors are not entitled to the specific investor protection provided by the Swiss Collective Investment Schemes Act (CISA).

Structured products are complex and involve a high risk. The intrinsic value of the investment instruments depends not only on the performance of the underlying asset, but also on the issuer's creditworthiness (credit risk), which can change over the duration of the product. In relation to any securities, currencies, financial instruments or other assets underlying a transaction to which this material relates, the values may fall as well as rise and past performance is not an indication of future performance. Before entering into any transaction, you should consult your own legal, supervisory, tax, financial and accounting advisors as you consider necessary. You should also make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) at your own discretion and based on your consultation with advisors as you consider necessary. Unless expressly agreed otherwise in writing, UBS does not act as financial advisor or fiduciary in any transaction. The terms and conditions of an investment are subject solely to the detailed provisions, including risk considerations, contained in the relevant product documentation. The product documentation, i.e. the prospectus and the Key Information Document (KID), can be obtained from the website keyinvest.ch.en.ubs.com, by entering the relevant security / ISIN. Before you invest in a product, please read the current prospectus and the Key Information Document (KID) carefully and thoroughly. UBS makes no representations or warranties with regard to any information contained herein, which originates from independent sources. This publication may not be copied or reproduced without UBS's prior written permission.

Not for distribution in the United States or to US persons. © UBS 2026. All rights reserved. The key symbol and UBS are among the registered and unregistered trademarks of UBS. UBS prohibits the forwarding of this information without the approval of UBS.

Contact

keyinvest@ubs.com

+41 44 239 76 76*

ubs.com/keyinvest

*Please note that calls to numbers marked with * may be recorded. When you call these numbers, we assume that you consent to this practice.